Normunity
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 College St, New Haven, Connecticut, ...Phone Number
(203) 993-6580Website
www.normunity.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Normunity
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The companys lead program, NRM823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT. For more information, please visit www.normunity.com and follow us on LinkedIn.Explore more
Normunity Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Normunity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Normunity has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Normunity recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Normunity had a recent Job posting/layoffs
Check out if Normunity is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Normunity
Normunity, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Normunity has new funding data
Product Launch: Get notified when Normunity launches new products
Recommended Actions
Find VP level buyers at Normunity
Find 3 more new buyers
Compare Similar Companies to Normunity
Compare insights from companies similar to Normunity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Normunity is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Normunity is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Normunity.
Normunity financials insights
Gather financial insights about Normunity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$65M
2025
Series B
$75M
Normunity Tech Stack
A closer look at the technologies used by Normunity
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
Executive Move
Board of Directors
New Hire
Executive Move
Funding
Normunity News & Media
Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumorsNormunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms
BOSTON & NEW HAVEN, Conn.--(BUSINESS WIRE)--Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The financing was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut InnovationNormunity appoints industry leader Debanjan Ray to Board of Directors
BOSTON & WEST HAVEN, Conn.--(BUSINESS WIRE)--Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Debanjan Ray, MBA, to its board of directors. Mr. Ray currently serves as President and Chief Executive Officer of Synthekine, and he has served in leadership roles for multiple biotechnology companies. “We are excited to welcome Debanjan to our Board of Directors, as he brings exceptional strategic, operational, and transNormunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer
BOSTON & WEST HAVEN, Conn.--(BUSINESS WIRE)--Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer. Ms. Granaturova brings over 25 years in the global biopharma industry with multi-disciplinary experience in corporate strategy, business development, R&D organization, portfolio management, and regulatory and commercialization strategies in b
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Normunity
Sign Up For FreeTo access detailed company insights
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, inclu... Read More
